| Thomas Derleth, MD | |
|
4545 Cordata Pkwy, Bellingham, WA 98226-7123 | |
| (360) 738-2200 | |
| Not Available |
| Full Name | Thomas Derleth |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 4545 Cordata Pkwy, Bellingham, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477550978 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD00012694 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Derleth, MD 4545 Cordata Pkwy, Bellingham, WA 98226-7123 Ph: (360) 738-2200 | Thomas Derleth, MD 4545 Cordata Pkwy, Bellingham, WA 98226-7123 Ph: (360) 738-2200 |
News Archive
Hearings in the House and Senate Wednesday examined public and private efforts to address health care fraud. And the Government Accountability Office issued a new report on fraudulent or improper billing to Medicare.
Peter Lee, who has steered California's Affordable Care Act marketplace since late 2011 and helped mold it into a model of what the federal health care law could achieve, announced Thursday he will leave his post in March.
The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells (ADRCs) for the treatment of no-option chronic heart disease patients showed the following: the procedure was safe and feasible; it demonstrated a statistically significant improvement in maximum oxygen consumption and patients' aerobic capacity measured as metabolic equivalents
Western States Biopharmaceuticals, Inc., a privately-held biotechnology company focusing on the development of novel therapies to treat inflammatory disease, and the University of Colorado announced today that they have entered into a licensing agreement for approaches to inhibiting newly discovered T cell Cytokine Inducing Surface Molecules, or TCISM autoimmune disease drug discovery targets.
A Cleveland Clinic-led research team has found that using an absorbable, antibiotic-eluting envelope when implanting cardiac devices like pacemakers and defibrillators can cut the rate of major infections by 40 percent.
› Verified 3 days ago
Katherine Morgan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2592 Kwina Rd, Bellingham, WA 98226 Phone: 360-384-0464 | |
Hannah Sheinin, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2979 Squalicum Pkwy, Suite 301, Bellingham, WA 98225 Phone: 360-734-1420 Fax: 360-756-6666 | |
Ankur Mogla, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 410 Birchwood Ave Ste 200, Bellingham, WA 98225 Phone: 360-734-9233 | |
Dr. Sumner Todd Mcallister, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 722 N State St, Bellingham, WA 98225 Phone: 360-752-2865 | |
Amir Gharaei, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3015 Squalicum Pkwy, Suite 140, Bellingham, WA 98225 Phone: 360-788-6112 | |
Scott Michael Letellier, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3301 Squalicum Pkwy, Bellingham, WA 98225 Phone: 360-788-8222 Fax: 360-788-7759 | |
Dr. Sukhjit Singh Shergill, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4545 Cordata Pkwy, Suite 2b, Bellingham, WA 98226 Phone: 360-738-2200 Fax: 360-752-5683 |